Drug Design Development and Therapy

Scope & Guideline

Transforming Pharmaceutical Science with Cutting-Edge Insights

Introduction

Immerse yourself in the scholarly insights of Drug Design Development and Therapy with our comprehensive guidelines detailing its aims and scope. This page is your resource for understanding the journal's thematic priorities. Stay abreast of trending topics currently drawing significant attention and explore declining topics for a full picture of evolving interests. Our selection of highly cited topics and recent high-impact papers is curated within these guidelines to enhance your research impact.
LanguageEnglish
ISSN1177-8881
PublisherDOVE MEDICAL PRESS LTD
Support Open AccessYes
CountryNew Zealand
TypeJournal
Convergefrom 2007 to 2024
AbbreviationDRUG DES DEV THER / Drug Des. Dev. Ther.
Frequency1 issue/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressPO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND

Aims and Scopes

The journal 'Drug Design Development and Therapy' focuses on advancing the field of drug development and therapeutic strategies through rigorous research that encompasses a variety of methodologies and disciplines.
  1. Drug Discovery and Development:
    The journal emphasizes original research articles that explore novel drug candidates, their mechanisms of action, and the methodologies involved in the drug development process.
  2. Pharmacology and Toxicology:
    Articles in this area assess the pharmacokinetics, pharmacodynamics, and toxicological profiles of various compounds, providing critical insights into their therapeutic potential.
  3. Clinical Applications and Trials:
    The journal publishes clinical studies, trials, and retrospective analyses that evaluate the efficacy and safety of drugs and treatment protocols in real-world settings.
  4. Integrative Approaches in Medicine:
    Research that combines traditional medicine with modern pharmacological techniques, particularly those utilizing network pharmacology and systems biology, is a significant focus.
  5. Innovative Drug Delivery Systems:
    The journal covers advancements in drug delivery technologies, including nanotechnology and biopolymer-based systems, aimed at enhancing therapeutic efficacy and patient compliance.
  6. Natural Products and Traditional Medicine:
    There is a consistent focus on the pharmacological properties of natural compounds and traditional medicine formulations, illustrating their roles in modern therapeutic applications.
The journal has observed notable trends and emerging themes that highlight its dynamic nature and responsiveness to contemporary issues in drug design and therapy.
  1. Network Pharmacology and Systems Biology:
    There is a growing trend towards the use of network pharmacology and systems biology approaches to understand drug interactions, mechanisms of action, and to identify therapeutic targets.
  2. Personalized Medicine:
    Research focusing on personalized or precision medicine is on the rise, reflecting a shift towards tailoring therapies based on individual patient profiles and genetic backgrounds.
  3. Integrative and Complementary Approaches:
    There is an increasing interest in the integration of traditional medicine with modern pharmacological methods, exploring the efficacy of herbal and natural products in contemporary therapeutic applications.
  4. Nanotechnology in Drug Delivery:
    The application of nanotechnology in drug delivery systems is emerging as a critical area of focus, aimed at improving bioavailability and targeting specific tissues or cells.
  5. Longitudinal and Real-World Evidence Studies:
    The journal is increasingly publishing longitudinal studies and real-world evidence research that assess the long-term efficacy and safety of treatments in diverse patient populations.
  6. Immunotherapy and Biologics:
    There is a noticeable trend towards research in immunotherapeutic agents and biologics, reflecting the growing importance of these therapies in the treatment of various diseases, particularly cancers.

Declining or Waning

While the journal continues to thrive in several research areas, some themes have shown a decline in prominence, reflecting changing priorities and advancements in the field.
  1. Conventional Pharmaceutical Approaches:
    Research focused solely on conventional pharmaceutical drugs without consideration of integrative or novel approaches appears to be waning, as the field shifts towards more innovative and holistic strategies.
  2. Single-Agent Studies:
    There is a noticeable reduction in studies that evaluate the efficacy of single-agent therapies, as combination therapies and multi-target strategies become more favorable in clinical settings.
  3. Basic Science Studies:
    Research with a purely basic science focus, lacking translational or clinical relevance, is increasingly less common, as the journal emphasizes studies with direct implications for drug development and therapy.
  4. Short-Term Efficacy Studies:
    The focus on short-term efficacy and safety studies is diminishing, with a greater emphasis now being placed on long-term outcomes and the comprehensive assessment of therapeutic regimens.

Similar Journals

BIOLOGICAL & PHARMACEUTICAL BULLETIN

Bridging the Gap Between Science and Healthcare
Publisher: PHARMACEUTICAL SOC JAPANISSN: 0918-6158Frequency: 12 issues/year

BIOLOGICAL & PHARMACEUTICAL BULLETIN, published by the PHARMACEUTICAL SOC JAPAN, is a prominent peer-reviewed journal that serves the fields of medicine, pharmaceutical science, and pharmacology. With an ISSN of 0918-6158 and an E-ISSN of 1347-5215, this publication has been crucial in disseminating innovative research since its inception in 1993, and it continues to contribute significantly to the body of knowledge as it converges towards 2024. Despite being classified as a non-open access journal, it maintains a respectable Q3 ranking in Medicine (miscellaneous) and Q2 in Pharmaceutical Science, highlighting its critical role in advancing scientific discourse in these areas. With Scopus rankings placing it in the 51st percentile for Pharmaceutical Science and 38th percentile for Pharmacology, BIOLOGICAL & PHARMACEUTICAL BULLETIN is an essential resource for researchers, professionals, and students looking to stay abreast of cutting-edge developments and trends in biomedicine and drug development.

INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS

Empowering healthcare through cutting-edge pharmacological studies.
Publisher: DUSTRI-VERLAG DR KARL FEISTLEISSN: 0946-1965Frequency: 12 issues/year

INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, published by DUSTRI-VERLAG DR KARL FEISTLE in Germany, is a vital scholarly platform dedicated to advancing the field of pharmacology through rigorous research and innovative therapeutic strategies. Established in 1994, this journal has maintained its relevance in the evolving landscape of clinical pharmacology, achieving a Q3 rank in both general and medical pharmacology categories as of 2023. With an ISSN of 0946-1965, it is positioned as an essential resource for researchers, healthcare professionals, and students seeking to enhance their understanding of drug therapy and pharmacological applications. Though it currently does not offer open access, its comprehensive scope covers a wide array of topics within pharmacology, promising to contribute significantly to scientific discussions and knowledge dissemination from 1994 to 2024. Whether you are looking for the latest studies or historical insights, the journal remains a fixture for anyone invested in the pharmacological sciences.

Chemical Biology & Drug Design

Fostering breakthroughs in molecular medicine and drug design.
Publisher: WILEYISSN: 1747-0277Frequency: 12 issues/year

Chemical Biology & Drug Design, an esteemed publication by WILEY, serves as a vital platform for the dissemination of pioneering research in the interdisciplinary fields of biochemistry, drug discovery, molecular medicine, organic chemistry, and pharmacology. With a dedicated commitment to advancing the understanding of chemical interactions and drug development, this journal not only fosters innovation but also bridges the gap between theoretical research and practical applications. It boasts an impressive impact factor and is recognized in the 2023 category quartiles as Q3 in Biochemistry and Molecular Medicine, and Q2 in Drug Discovery, Organic Chemistry, and Pharmacology, indicating its relevance and influence in these crucial areas. The journal’s rankings across various Scopus categories further solidify its position as a reputable resource for researchers, professionals, and students striving to stay at the forefront of medicinal chemistry and drug design. While primarily traditional access-based, the journal's evolving scope from 2006 to 2024 ensures an ongoing contribution to essential scientific dialogue, making it an indispensable read for those committed to advancing health sciences.

Current Computer-Aided Drug Design

Exploring New Horizons in Drug Design and Molecular Medicine
Publisher: BENTHAM SCIENCE PUBL LTDISSN: 1573-4099Frequency: 4 issues/year

Current Computer-Aided Drug Design, published by BENTHAM SCIENCE PUBL LTD, is a pivotal journal dedicated to the integration of computer-aided methodologies within the drug design process. With its ISSN 1573-4099 and E-ISSN 1875-6697, this journal serves as a vital resource for researchers, professionals, and students interested in advancing the fields of pharmacology and molecular medicine. Operating under a framework that spans from 2006 to 2024, it aims to foster innovative approaches and discussions surrounding drug design strategies, computational techniques, and the therapeutic potential of novel compounds. Although it currently holds a Q4 rating in Drug Discovery and Molecular Medicine as well as a Q3 in Medicine (miscellaneous) within the 2023 category quartiles, the journal continues to enhance its visibility and relevance in the academic community. Its Scopus rankings reflect its commitment to quality research, positioning it in the context of drug discovery and molecular studies. As the field of drug design evolves, Current Computer-Aided Drug Design remains an essential platform for disseminating cutting-edge findings and facilitating collaboration among specialists aiming for significant advancements in drug development.

DRUG DEVELOPMENT RESEARCH

Pioneering insights in pharmacology and toxicology.
Publisher: WILEYISSN: 0272-4391Frequency: 8 issues/year

DRUG DEVELOPMENT RESEARCH is a premier interdisciplinary journal published by Wiley, focusing on the latest advancements in drug discovery, pharmacology, and toxicology. With an ISSN of 0272-4391 and an E-ISSN of 1098-2299, this esteemed publication has been a cornerstone in the field since its inception in 1981 and continues to provide cutting-edge research until 2024. Its rigorous peer-review process and strategic placement in Q2 of the Drug Discovery category, as well as ranking #60 out of 157 in Scopus, underscore the journal's relevance and influence, boasting a respectable 62nd percentile ranking. While the journal does not currently offer open access, it remains a vital resource for researchers, professionals, and students seeking to expand their knowledge on the processes of drug development, identifying new therapeutic targets, and assessing the efficacy and safety of novel compounds. Situated in Hoboken, NJ, this journal stands at the forefront of pharmaceutical innovation, making significant contributions to the advancement of medical science.

JOURNAL OF PHARMACY AND PHARMACOLOGY

Pioneering research for transformative healthcare solutions.
Publisher: OXFORD UNIV PRESSISSN: 0022-3573Frequency: 12 issues/year

Journal of Pharmacy and Pharmacology, published by Oxford University Press, is a prestigious academic journal dedicated to the advancement of knowledge in the fields of pharmaceutical sciences and pharmacology. With a strong heritage dating back to 1949, this journal maintains a robust influence, as evidenced by its ranking in the second quartile (Q2) across both Pharmaceutical Science and Pharmacology categories for 2023. The journal is accessible without an open access option, ensuring traditional academic engagement and providing valuable insights for researchers and professionals. It boasts an impressive Scopus ranking, with a percentile positioning of 72nd in Pharmaceutical Science and 67th in Pharmacology. Aimed at fostering innovative research and facilitating the exchange of cutting-edge scientific knowledge, the Journal of Pharmacy and Pharmacology serves as an essential resource for scientists, students, and healthcare professionals committed to enhancing therapeutic outcomes and advancing pharmaceutical innovations.

Acta Pharmaceutica Sinica B

Pioneering Innovations in Drug Development
Publisher: INST MATERIA MEDICA, CHINESE ACAD MEDICAL SCIENCESISSN: 2211-3835Frequency: 6 issues/year

Acta Pharmaceutica Sinica B is a prestigious open access journal that has been setting the standard in the field of pharmacology, toxicology, and pharmaceutics since its establishment in 2011. Published by the Institute of Materia Medica, Chinese Academy of Medical Sciences, the journal serves as a vital platform for researchers, professionals, and students seeking to disseminate innovative findings in drug development, pharmaceutical sciences, and therapeutic applications. With an impressive impact factor reflecting its high academic quality, Acta Pharmaceutica Sinica B has achieved Q1 status in the category of Pharmacology, Toxicology and Pharmaceutics as of 2023, ranking #1 out of 80 journals in General Pharmacology. This journal not only focuses on the latest advancements in drug research and formulation but also emphasizes interdisciplinary approaches, fostering collaborations that span various scientific domains. The accessible nature of the journal, combined with its rigorous peer-review process, ensures that crucial insights and breakthroughs reach a global audience swiftly and effectively. For those looking to stay at the forefront of pharmaceutical research, Acta Pharmaceutica Sinica B is an indispensable resource.

International Journal of Pharmacology

Advancing the Frontiers of Pharmacological Research
Publisher: ASIAN NETWORK SCIENTIFIC INFORMATION-ANSINETISSN: 1811-7775Frequency: 8 issues/year

Welcome to the International Journal of Pharmacology, a key publication in the field of pharmacology, published by ASIAN NETWORK SCIENTIFIC INFORMATION (ANSINET). Since its inception in 2006, this journal has provided a vital platform for researchers and professionals to disseminate their findings and insights in pharmacology, toxicology, and pharmaceutics. Despite recent discontinuation in Scopus coverage, the journal's dedication to fostering scientific dialogue continues to attract contributions from esteemed scholars globally. With an **ISSN of 1811-7775** and **E-ISSN of 1812-5700**, the journal seeks to bridge the gap between laboratory research and clinical application, promoting a deeper understanding of drug actions and interactions. Although it operates under traditional access options, the relevance of its published studies to ongoing pharmacological research remains significant.

ACTA PHARMACEUTICA

Advancing pharmaceutical innovation for a healthier tomorrow.
Publisher: SCIENDOISSN: 1330-0075Frequency: 4 issues/year

ACTA PHARMACEUTICA is a distinguished open-access journal published by SCIENDO, dedicated to advancing knowledge in the fields of medicine and pharmaceutical sciences. Established in 1992, the journal has made significant contributions to the scholarly community, providing a platform for innovative research and discussion. With a strong presence in both Q2 and Q3 quartiles across various categories including Pharmaceutical Science and Pharmacology, ACTA PHARMACEUTICA ranks favorably, positioning its contributions in the upper tiers of the field. The journal's commitment to open access since 2007 ensures that both practitioners and scholars have immediate access to cutting-edge developments, thereby fostering collaboration and knowledge sharing. With its scope spanning a broad spectrum of pharmaceutical and biomedical research, ACTA PHARMACEUTICA is an essential resource for researchers, professionals, and students keen to stay abreast of the latest advancements and trends in these vital areas of study.

DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY

Transforming Ideas into Effective Therapies
Publisher: TAYLOR & FRANCIS LTDISSN: 0363-9045Frequency: 12 issues/year

Drug Development and Industrial Pharmacy is a prestigious journal published by Taylor & Francis Ltd, focusing on the critical field of pharmaceutical sciences. With an ISSN of 0363-9045 and an E-ISSN of 1520-5762, the journal has been an essential resource for researchers and professionals since its inception in 1974. It occupies a crucial niche within Drug Discovery, Organic Chemistry, and Pharmaceutical Science, currently ranked in the second and third quartiles, reflecting its solid contribution to the field. The journal encompasses a wide array of topics, including drug development processes, formulation, and industrial manufacturing alongside cutting-edge research in pharmacology and toxicology. With a commendable Scopus ranking demonstrating high relevance—ranked #44 in Pharmaceutical Science—it serves as a vital forum for academia and industry to share innovative findings and methodologies. While it does not offer open access, the journal remains an invaluable resource for those seeking to advance their knowledge and enhance their research in pharmaceutical development.